Clinical Trial: A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06941272) titled 'A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)' on Feb. 27.

Brief Summary: Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory:

* Hepatoblastoma is a common liver cancer in babies and very young children

* RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs

* Relapsed means the cancer came back after treatment

* Refractory means the cancer did not respond (get smaller or go away) to treatment

The study treatment HER...